Article thumbnail

Bioassays to Monitor Taspase1 Function for the Identification of Pharmacogenetic Inhibitors

By Shirley K. Knauer, Verena Fetz, Jens Rabenstein, Sandra Friedl, Bettina Hofmann, Samaneh Sabiani, Elisabeth Schröder, Lena Kunst, Eugen Proschak, Eckhard Thines, Thomas Kindler, Gisbert Schneider, Rolf Marschalek, Roland H. Stauber and Carolin Bier
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3102056
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2009). A phosphorylation-acetylation switch regulates STAT1 signaling.
  2. (2010). An otoprotective role for the apoptosis inhibitor protein survivin. Cell Death and Disease;doi:10.1038/cddis.2010.25.
  3. (2007). Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions.
  4. (2004). Chemogenomics: an emerging strategy for rapid target and drug discovery.
  5. (2010). Cloning and functional characterization of the guinea pig apoptosis inhibitor protein Survivin.
  6. (2005). Crystal structure of human Taspase1, a crucial protease regulating the function of MLL.
  7. (2006). Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer.
  8. (2009). Design, syntheses, and evaluation of Taspase1 inhibitors.
  9. (2005). Development of an autofluorescent translocation biosensor system to investigate protein-protein interactions in living cells.
  10. (2006). DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair.
  11. (2009). Drug discovery and natural products: end of an era or an endless frontier?
  12. (2007). Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker.
  13. (2007). Emerging roles of proteases in tumour suppression.
  14. (2010). Expression analysis suggests a potential cytoprotective role of Birc5 in the inner ear.
  15. (2007). FRMD3, a novel putative tumour suppressor in NSCLC.
  16. Hsieh JJ,ChengEH,KorsmeyerSJ(2003)Taspase1:athreonineaspartaserequired for cleavage of MLL and proper HOX gene expression.
  17. (2010). Identification of cell surface glycoprotein markers for glioblastoma-derived stem-like cells using a lectin microarray and LC-MS/MS approach.
  18. (2010). Loss of DNA polymerase zeta enhances spontaneous tumorigenesis.
  19. (2010). Metalloproteases and the degradome.
  20. (2010). Mixed lineage leukemia: roles in human malignancies and potential therapy.
  21. (2008). NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas.
  22. (2007). Nuclear export is essential for the tumor-promoting activity of survivin.
  23. (2005). Nuclear export is evolutionarily conserved in CVC paired-like homeobox proteins and influences protein stability, transcriptional activation, and extracellular secretion.
  24. (2007). Optimizing the integration of immunoreagents and fluorescent probes for multiplexed high content screening assays.
  25. (2005). Patient-based cross-platform comparison of oligonucleotide microarray expression profiles.
  26. (2008). Protease proteomics: revealing protease in vivo functions using systems biology approaches.
  27. (2008). Proteases: multifunctional enzymes in life and disease.
  28. (2006). Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression.
  29. (2003). Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization.
  30. (2008). Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites.
  31. (2001). Qualitative highly divergent nuclear export signals can regulate export by the competition for transport cofactors in vivo.
  32. (2001). Rapid evaluation and optimization of recombinant protein production using GFP tagging. Protein Expression and Purification
  33. (2004). Receptor protein tyrosine phosphatase zeta as a therapeutic target for glioblastoma therapy.
  34. (2007). Species selectivity of mixed-lineage leukemia/ trithorax and HCF proteolytic maturation pathways.
  35. (2007). Survivin’s dual role: an export’s view.
  36. (2006). Targeting proteases: successes, failures and future prospects.
  37. (2010). The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.
  38. (2009). The Degradome database: mammalian proteases and diseases of proteolysis.
  39. (2008). The impact of natural products upon modern drug discovery.
  40. (2006). The MLL recombinome of acute leukemias.
  41. (2008). The PDZ and band 4.1 containing protein Frmpd1 regulates the subcellular location of activator of Gprotein signaling 3 and its interaction with G-proteins.
  42. (2006). The Survivin-Crm1 interaction is essential for chromosomal passenger complex localization and function.
  43. (1995). Transcriptional activation by tetracyclines in mammalian cells.
  44. (2009). Translocation Biosensors – Cellular System Integrators to Dissect CRM1-Dependent Nuclear Export by Chemicogenomics.
  45. (2005). Translocation biosensors to study signal-specific nucleo-cytoplasmic transport, protease activity and protein-protein interactions.
  46. (2006). Uncleaved TFIIA is a substrate for taspase 1 and active in transcription.
  47. (2010). Virtual screening: an endless staircase?
  48. (2009). Xanthepinone, an antimicrobial polyketide from a soil fungus closely related to Phoma medicaginis.